Certified by Founder
Lodge
T-Therapeutics Ltd
start up
United Kingdom
- Cambridge
- 16/11/2023
- Series A
- $59,707,000
T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
- Industry Biotechnology Research
- Website https://t-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/t-therapeutics/about/
JetScale AI | $5,400,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Profitmind | $9,000,000 | (Feb 26, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)
NationGraph | $18,000,000 | (Feb 26, 2026)